Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“H.C. Wainwright & Co.”) initially entered into on January 30, 2024. The at-the-market offering program en ...

Core Viewpoint - Snail, Inc. has entered into an At The Market Offering Agreement to sell up to $4,500,000 of its Class A Common Stock to support its digital asset initiative, including the potential introduction of a proprietary stablecoin backed by U.S. dollars [1][2]. Group 1: Offering Details - The Offering will be conducted under a Sales Agreement with H.C. Wainwright & Co. as the sales agent, allowing the company to sell shares from time to time in an at the market offering [1][3]. - The shares will be sold through methods permitted by law, including direct sales on the Nasdaq Capital Market [3]. - The Offering will be made only by means of a prospectus supplement filed with the SEC, which is part of the company's shelf registration statement [4]. Group 2: Use of Proceeds - The net proceeds from the sale of the shares will primarily be used for working capital to support the company's digital asset initiative, including the evaluation of a proprietary stablecoin [2]. Group 3: Company Overview - Snail, Inc. is a leading global independent developer and publisher of interactive digital entertainment, with a portfolio of premium games for various platforms [6].